ABSTRACT
Diffuse large B cell lymphoma （DLBCL） is a malignant tumor derived from mature B cells. Currently， chemotherapy is still the main clinical treatment. However， some patients experience recurrence or refractory conditions after treatment. On June 15， 2023， the FDA approved the marketing of glofitamab， a CD3/CD20 bispecific monoclonal antibody， to provide the new treatment plan for patients with recurrent or refractory DLBCL after receiving 2-line or above systemic treatment. This article reviews pharmacological effects， clinical studies， safety， usage and dosage of glofitamab. Glofitamab mainly plays a therapeutic role in DLBCL by promoting the activation and proliferation of T cells，activating T cells to release tumor cell-killing proteins， and mediating the lysis of B cells. Clinical studies have shown that glofitamab has a better complete and objective response rate for recurrent or refractory DLBCL. Common adverse reactions caused by glofitamab include mild/moderate cytokine release syndrome， musculoskeletal pain， rash， fatigue， and so on，without significant drug interactions.
ABSTRACT
The views from teachers and residents were analyzed to discusses the problems existing in the standardized training of TCM residents,and try to find the solution.A total of 98 standardized training residents and 111 teachers from Dongfang Hospital affiliated to Beijing University of Chinese Medicine (BUCM) were enrolled.The questionnaire sceened by star APP on the phone was used to investigate them with six practical questions,each of which had three options.Both groups agreed that undergraduates' rotate period for 3 years,masters' period for 2 years,and doctors' period for 1 year.As to the item of TCM hospital selection,both groups chose traditional Chinese medicine hospital for resident standardization training.As to the item of majors,59 teachers (53.2％) and 67 (68.4％) residents chose to learn their majors.The teachers suggested that student independent management can improve sense of presence in the department.But 36.7％ of residents considered increasing income can improve sense of presence.There are some problems in TCM residents training system,and we suggest that it should be proceeding from reality in residents and constantly improved in the future.
ABSTRACT
Objective To investigate the inhibitory effect of bone marrow mesenchymal stem cells ( BMMSC) on the inflammatory response of microglial cells .Methods The samples were divided into four groups .Group I:microglial (BV-2) cells were cultured in DMEM (high glucose).Group II: BV-2 cells were cultured in DMEM containing lipopo-lysaccharide (LPS).Group III:BV-2cells and BMMSCs were co-cultured in DMEM.Group IV: BMMSCs were cultured in DMEM containing LPS .The growth state and ultrastructure of BV-2 cells were observed and the changes of TNF-αex-pression were detected .Results Different cell densities of BV-2 cells were observed under the optical microscope in an or-der from high level to low level:group I >group III >group II.The expressions of TNF-αwere:group Ⅱ >groupⅢ>group Ⅰ.Ultrastructural observation of BV-2 cells showed that there were a large number of swollen mitochondria and endoplasmic reticulum , some of them showed vacuolization .No BV-2 cells with multiple hucleoli were found in the group II indicating the absence of active cell growth .At the same time, cytolysis was observed only in the group II .The growth of BV-2 cells in the group III was better than that in the group II .Conclusions BMMSCs can inhibit inflammatory response of microglial cells, therefore, play a neuroprotective role.